Complete Filing Data
MAIA Biotechnology, Inc. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $8.51 million for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean MAIA Biotechnology, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$22.4M | -$23.3M | -$19.8M | -$15.8M | -$12.6M |
| General And Administrative Expense | $9.7M | $6.9M | $9.1M | $6.1M | $4.3M |
| Comprehensive Income Net Of Tax | -$22.4M | -$23.3M | -$19.8M | -$16.2M | -$12.5M |
| Operating Income Loss | -$24.3M | -$17.0M | -$20.2M | -$16.2M | -$7.8M |
| Net Income Loss Available To Common Stockholders Basic | -$22.4M | -$23.3M | -$19.8M | -$16.2M | -$12.5M |
| Research And Development Expense | $10.0M | $11.1M | $8.9M | $3.5M | |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$19.6K | -$14.4K | -$287.00 | -$16.0K | |
| Australian Research And Development Incentives | $80.0K | $176.7K | $313.6K | $43.7K | |
| Interest Expense | $57.00 | $6.9K | $7.0K | $827.5K | |
| Operating Expenses | $24.3M | $17.0M | $20.2M | $16.2M | $7.8M |
| Research And Development Incentives Receivable | $77.3K | $144.7K | $302.8K | $43.7K | |
| Net Income Loss Attributable To Noncontrolling Interest | -$74.3K | ||||
| Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent | -$19.6K | -$14.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$8.9M | -$5.3M | -$4.5M | -$2.7M | -$8.9M | -$8.1M | -$4.9M | -$4.5M | -$4.1M | -$4.9M | -$3.3M | -$3.4M | -$5.2M | -$3.4M | -$1.5M |
| General And Administrative Expense | $3.0M | $2.1M | $2.2M | $1.5M | $1.8M | $1.6M | $2.4M | $2.1M | $2.0M | $1.7M | $1.3M | $1.4M | $1.2M | $859.3K | |
| Comprehensive Income Net Of Tax | -$8.9M | -$5.3M | -$4.5M | -$2.7M | -$8.9M | -$8.1M | -$4.9M | -$4.5M | -$4.1M | -$5.0M | -$3.3M | -$3.9M | -$5.2M | -$3.4M | |
| Operating Income Loss | -$9.4M | -$5.2M | -$5.4M | -$4.2M | -$3.8M | -$3.9M | -$5.0M | -$4.7M | -$4.2M | -$5.1M | -$3.4M | -$3.4M | -$2.2M | ||
| Net Income Loss Available To Common Stockholders Basic | -$8.9M | -$5.3M | -$4.5M | -$2.7M | -$8.9M | -$8.1M | -$4.9M | -$4.5M | -$4.1M | -$4.9M | -$3.3M | -$3.9M | -$5.2M | ||
| Research And Development Expense | $3.2M | $2.7M | $2.1M | $2.3M | $2.6M | $2.6M | $2.2M | $2.3M | $2.1M | $2.1M | $1.1M | $644.0K | |||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$807.00 | $8.1K | -$7.5K | $10.5K | $7.9K | -$13.8K | -$17.9K | -$634.00 | -$9.3K | -$47.5K | -$5.9K | $1.7K | |||
| Australian Research And Development Incentives | $15.2K | $18.0K | $18.6K | $58.4K | $39.8K | $51.2K | $65.1K | $135.8K | $29.2K | ||||||
| Interest Expense | $85.00 | $1.00 | $1.7K | $5.1K | $1.7K | $104.00 | $451.3K | $313.5K | |||||||
| Operating Expenses | $9.4M | $5.2M | $5.4M | $4.2M | $3.8M | $3.9M | $5.0M | $4.7M | $4.2M | $5.1M | $3.4M | $3.4M | |||
| Research And Development Incentives Receivable | $82.7K | $82.3K | $78.1K | $53.6K | $177.7K | $156.0K | $114.4K | $386.8K | $348.4K | $255.3K | $203.2K | ||||
| Net Income Loss Attributable To Noncontrolling Interest | -$7.1K | -$29.7K | |||||||||||||
| Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent | -$807.00 | $8.1K | -$7.5K | $10.5K | $7.9K | -$13.8K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity * | $2.4M | $3.6M | $477.5K | $8.5M | $9.2M | -$1.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $11.0M | $10.6M | $663.5K | |||
| Retained Earnings Accumulated Deficit | -$109.6M | -$87.2M | -$64.0M | -$44.2M | -$28.4M | |
| Liabilities And Stockholders Equity | $9.7M | $10.2M | $7.6M | $12.0M | $11.3M | |
| Liabilities | $7.3M | $6.5M | $7.1M | $3.5M | $2.1M | |
| Common Stock Value | $3.9K | $2.6K | $1.7K | $1.1K | $758.00 | |
| Assets Current | $9.7M | $10.2M | $7.6M | $11.8M | $10.7M | |
| Assets | $9.7M | $10.2M | $7.6M | $12.0M | $11.3M | |
| Accounts Payable Current | $2.0M | $1.5M | $1.6M | $1.2M | $960.4K | |
| Prepaid Expense And Other Assets Current | $1.0M | $473.8K | $268.7K | $554.3K | $54.5K | |
| Other Assets Noncurrent | $2.8K | $2.8K | $2.8K | $2.8K | $3.1K | |
| Accrued Liabilities Current | $3.8M | $2.3M | $3.3M | $2.1M | $1.2M | |
| Liabilities Current | $5.8M | $3.8M | $4.9M | $3.3M | $2.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $2.5M | -$3.8M | $376.6K | $9.9M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$50.2K | -$30.6K | -$16.3K | -$16.0K | ||
| Issuance Of Common Shares In Connection With Equity Financing | 2.5M | 5.9M | ||||
| Warrant Liability Noncurrent | $2.2M | $245.3K | ||||
| Deferred Costs | $211.2K | $651.6K | ||||
| Options Issued For Accrued Bonus | $974.2K | $786.5K | ||||
| Issuance Of Stock Options To Satisfy Accrued Bonus | $974.2K | $786.5K | ||||
| Reclassification Of Warrant Liability To Equity | $2.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $41.7K | $3.9M | $4.9M | $3.6M | $1.6M | $3.2M | -$5.8M | $477.5K | $2.7M | $6.9M | $5.1M | $12.1M | $6.7M | $9.0M | $10.2M | -$3.7M | -$2.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $10.9M | $9.6M | $8.7M | $11.6M | $8.3M | $7.2M | $6.1M | $9.1M | $7.6M | $14.1M | $8.2M | $10.3M | $11.0M | $6.8M | |||
| Retained Earnings Accumulated Deficit | -$106.0M | -$97.1M | -$91.8M | -$83.7M | -$80.9M | -$72.0M | -$57.7M | -$52.8M | -$48.3M | -$39.1M | -$35.2M | ||||||
| Liabilities And Stockholders Equity | $11.8M | $11.0M | $11.9M | $9.2M | $12.0M | $8.7M | $7.0M | $10.3M | $9.1M | $14.8M | $9.8M | ||||||
| Liabilities | $11.7M | $7.2M | $6.9M | $7.6M | $8.9M | $14.5M | $4.3M | $3.4M | $4.0M | $2.5M | $3.1M | ||||||
| Common Stock Value | $3.4K | $3.2K | $3.0K | $2.4K | $2.4K | $2.1K | $1.4K | $1.4K | $1.1K | $1.1K | $842.00 | ||||||
| Assets Current | $11.8M | $11.0M | $11.9M | $9.2M | $12.0M | $8.7M | $6.6M | $9.8M | $8.3M | $14.8M | $8.6M | ||||||
| Assets | $11.8M | $11.0M | $11.9M | $9.2M | $12.0M | $8.7M | $7.0M | $10.3M | $9.1M | $14.8M | $9.8M | ||||||
| Accounts Payable Current | $3.2M | $1.7M | $1.8M | $1.2M | $1.3M | $1.9M | $1.2M | $1.5M | $1.1M | $1.0M | $1.0M | ||||||
| Prepaid Expense And Other Assets Current | $780.5K | $816.3K | $920.5K | $495.7K | $259.7K | $272.6K | $414.1K | $243.3K | $398.9K | $460.9K | $256.5K | ||||||
| Other Assets Noncurrent | $27.1K | $2.8K | $2.8K | $2.8K | $2.8K | $2.8K | $2.8K | $2.8K | $2.8K | $2.8K | $2.8K | ||||||
| Accrued Liabilities Current | $6.8M | $3.3M | $3.2M | $2.5M | $2.2M | $3.0M | $2.9M | $1.7M | $2.6M | $1.4M | $2.1M | ||||||
| Liabilities Current | $10.0M | $5.0M | $5.1M | $3.6M | $3.5M | $4.9M | $4.1M | $3.3M | $3.8M | $3.1M | |||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.3M | $1.1M | -$3.4M | -$280.8K | |||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$30.8K | -$30.0K | -$38.2K | -$11.7K | -$22.2K | -$30.0K | -$43.8K | -$25.9K | -$25.3K | -$51.6K | -$4.1K | ||||||
| Issuance Of Common Shares In Connection With Equity Financing | 100.0K | 2.4M | 5.5M | ||||||||||||||
| Warrant Liability Noncurrent | $1.9M | $2.7M | $4.0M | $5.3M | $9.6M | $103.4K | $121.6K | $224.4K | |||||||||
| Deferred Costs | $13.2K | $0.00 | $365.1K | $489.6K | $737.7K | $1.1M | |||||||||||
| Options Issued For Accrued Bonus | |||||||||||||||||
| Issuance Of Stock Options To Satisfy Accrued Bonus | $974.2K | $786.5K | |||||||||||||||
| Reclassification Of Warrant Liability To Equity | $2.0M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Proceeds From Issuance Of Common Stock | $327.6K | $658.8K | $2.5M | $5.7M | |
| Share Based Compensation | $2.6M | $1.9M | $3.1M | $2.3M | $2.7M |
| Net Cash Provided By Used In Operating Activities | -$18.8M | -$15.7M | -$13.1M | -$12.1M | -$4.1M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $579.8K | $195.9K | -$285.8K | $505.2K | $15.2K |
| Increase Decrease In Accrued Liabilities | $1.5M | -$979.8K | $2.2M | $915.7K | $997.1K |
| Increase Decrease In Accounts Payable | $519.7K | -$118.8K | $471.9K | $211.3K | $805.5K |
| Net Cash Provided By Used In Financing Activities | $17.9M | $18.2M | $9.3M | $12.5M | $14.0M |
| Proceeds From Stock Options Exercised | $844.00 | $217.2K | $1.4K | $84.0K | $9.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$5.2K | -$21.5K | -$117.00 | -$4.4K | |
| Increase Decrease In Other Operating Assets | -$322.00 | $3.1K | |||
| Proceeds From Warrant Exercises | $901.6K | $385.4K | $529.4K | ||
| Increase Decrease In Receivables | -$158.4K | $269.4K | |||
| Proceeds From Issuance Initial Public Offering | $7.2M | $10.1M | $11.5M | ||
| Increase Decrease In Research And Development Incentives Receivable | -$80.4K | -$56.8K | -$158.4K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|
| Proceeds From Issuance Of Common Stock | $117.1K | $61.1K | $130.2K | $63.8K | $315.3K | $179.6K | $2.4M | |
| Share Based Compensation | $371.5K | $350.0K | $537.5K | $713.3K | ||||
| Net Cash Provided By Used In Operating Activities | -$4.2M | -$3.6M | -$3.4M | -$2.8M | ||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $456.8K | -$67.1K | -$153.8K | $134.3K | ||||
| Increase Decrease In Accrued Liabilities | $867.2K | -$275.8K | $8.2K | $352.9K | ||||
| Increase Decrease In Accounts Payable | $359.1K | $237.0K | -$35.2K | -$67.1K | ||||
| Net Cash Provided By Used In Financing Activities | $5.5M | $4.7M | $2.5M | |||||
| Proceeds From Stock Options Exercised | $844.00 | $47.7K | ||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $3.1K | -$9.5K | -$4.0K | -$4.3K | ||||
| Increase Decrease In Other Operating Assets | -$322.00 | |||||||
| Proceeds From Warrant Exercises | $110.0K | |||||||
| Increase Decrease In Receivables | $51.2K | |||||||
| Proceeds From Issuance Initial Public Offering | ||||||||
| Increase Decrease In Research And Development Incentives Receivable | $18.6K | $51.2K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 32.1M | 22.2M | 13.3M | 9.3M | 5.3M |
| Earnings Per Share Diluted | $-0.70 | $-1.05 | $-1.49 | $-1.75 | $-2.37 |
| Weighted Average Number Of Diluted Shares Outstanding | 32.1M | 22.2M | 13.3M | 9.3M | 5.3M |
| Preferred Stock Shares Authorized | 30.0M | 30.0M | 30.0M | 30.0M | 70.0M |
| Earnings Per Share Basic | $-0.70 | $-1.05 | $-1.49 | $-1.75 | $-2.37 |
| Common Stock Shares Authorized | 150.0M | 70.0M | 70.0M | 70.0M | 30.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Shares Issued | 38.6M | 26.2M | 17.0M | 11.0M | 7.6M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Shares Outstanding | 38.6M | 26.2M | 17.0M | 11.0M | 7.6M |
| Consulting Expense For Restricted Shares Issued | 179.5K | 731.7K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 33.2M | 30.3M | 27.7M | 23.9M | 22.2M | 17.6M | 13.7M | 12.9M | 11.0M | 10.2M | 8.2M | 7.8M | 5.1M | 4.4M | |
| Earnings Per Share Diluted | $-0.27 | $-0.18 | $-0.16 | $-0.11 | $-0.40 | $-0.46 | $-0.36 | $-0.35 | $-0.38 | $-0.48 | $-0.40 | $-0.50 | $-1.02 | $-0.78 | |
| Weighted Average Number Of Diluted Shares Outstanding | 33.2M | 30.3M | 27.7M | 23.9M | 22.2M | 17.6M | 13.7M | 12.9M | 11.0M | 10.2M | 8.2M | 7.8M | 5.1M | 4.4M | |
| Preferred Stock Shares Authorized | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 30.0M | 70.0M | ||||
| Earnings Per Share Basic | $-0.27 | $-0.18 | $-0.16 | $-0.11 | $-0.40 | $-0.46 | $-0.36 | $-0.35 | $-0.38 | $-0.48 | $-0.40 | $-0.50 | $-1.02 | $-0.78 | |
| Common Stock Shares Authorized | 150.0M | 150.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 70.0M | 30.0M | 100.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.0M | |||
| Common Stock Shares Issued | 34.5M | 31.8M | 29.6M | 24.0M | 23.7M | 20.6M | 13.8M | 13.6M | 11.0M | 10.9M | 8.4M | 30.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Common Stock Shares Outstanding | 34.5M | 31.8M | 29.6M | 24.0M | 23.7M | 20.6M | 13.8M | 13.6M | 11.0M | 10.9M | 8.4M | ||||
| Consulting Expense For Restricted Shares Issued | 11.5K | 164.1K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.6M | $1.9M | $3.1M | $2.3M | $2.4M |
| Other Operating Income Expense Net | $1.9M | -$6.3M | $409.5K | $406.9K | -$4.8M |
| Fair Value Adjustment Of Warrants | -$1.2M | $6.7M | -$205.1K | -$98.4K | $1.5M |
| Investment Income Interest | $318.4K | $34.5K | $1.9K | $2.0K | |
| Foreign Currency Translation Adjustment | -$14.4K | -$287.00 | -$16.0K | ||
| Stock Issued During Period Value Stock Options Exercised | $844.00 | $217.2K | $1.4K | $84.0K | $9.0K |
| Additional Paid In Capital | $112.1M | $90.9M | $64.5M | $52.7M | $37.6M |
| Stock Issued During Period Value Restricted Stock Award Gross | $618.8K | $179.5K | $731.7K | $27.5K | |
| Issuance Of Common Shares Upon Exercise Of Warrants | 385.4K | 529.4K | |||
| Operating Costs And Expenses | |||||
| Stock Issued During Period Shares Stock Options Exercised | 570.00 | 120.1K | 750.00 | 46.5K | |
| Payment Of Offering Transactions Costs | $617.1K | $795.3K | $2.1M | ||
| Change In Fair Value Of Embedded Features | $203.0K | ||||
| Stock Issued During Period Value New Issues | $6.9M | $9.5M | |||
| Deemed Dividend On Warrant Modification | -$450.6K | ||||
| Ratchet Share Expense | $1.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $646.9K | $802.5K | $371.5K | $455.4K | $413.9K | $350.0K | $570.9K | $618.9K | $537.5K | $532.4K | $584.8K | $713.3K | $746.3K | $660.0K | $408.6K |
| Other Operating Income Expense Net | $457.7K | -$180.9K | $908.2K | $1.5M | -$5.1M | -$4.1M | $79.9K | $141.0K | $67.4K | $191.8K | $136.2K | $29.7K | -$3.0M | -$2.0M | |
| Fair Value Adjustment Of Warrants | -$379.3K | $260.6K | -$826.0K | -$1.3M | $5.2M | $4.2M | -$18.2K | -$102.8K | -$20.9K | -$128.0K | $100.8K | $1.6M | |||
| Investment Income Interest | $79.7K | $82.2K | $106.1K | $88.4K | $44.1K | $3.3K | $172.00 | $336.00 | $348.00 | $429.00 | $472.00 | $708.00 | $652.00 | ||
| Foreign Currency Translation Adjustment | -$7.5K | $10.5K | $7.9K | -$13.8K | -$17.9K | -$634.00 | -$9.3K | -$47.5K | -$5.9K | $1.7K | |||||
| Stock Issued During Period Value Stock Options Exercised | $844.00 | $30.2K | $185.6K | $1.4K | $18.0K | $47.7K | $5.4K | ||||||||
| Additional Paid In Capital | $106.1M | $101.0M | $96.7M | $85.3M | $84.1M | $66.3M | $60.5M | $59.7M | $53.4M | $51.5M | $41.8M | ||||
| Stock Issued During Period Value Restricted Stock Award Gross | $187.3K | $62.3K | $100.0K | $11.5K | $194.6K | $324.3K | $164.1K | $27.5K | |||||||
| Issuance Of Common Shares Upon Exercise Of Warrants | 275.4K | 110.0K | |||||||||||||
| Operating Costs And Expenses | $4.0M | $3.4M | $2.2M | $1.5M | |||||||||||
| Stock Issued During Period Shares Stock Options Exercised | 570.00 | ||||||||||||||
| Payment Of Offering Transactions Costs | $204.7K | $276.9K | |||||||||||||
| Change In Fair Value Of Embedded Features | $96.0K | $92.0K | |||||||||||||
| Stock Issued During Period Value New Issues | $3.7M | $1.4M | $1.4M | $596.6K | $6.8M | $565.6K | $4.2M | ||||||||
| Deemed Dividend On Warrant Modification | -$450.6K | ||||||||||||||
| Ratchet Share Expense | $1.1M |
Most recent annual filing with the SEC: March 23, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.